An Automated Insulin Delivery System with Automatic Meal Bolus Based on a Hand-Gesturing Algorithm
Diabetes Technology & Therapeutics · 2024-09 · 26 (9) · 633-643
DOI: 10.1089/dia.2023.0529 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 04.09.2024. Verfasst von Anirban Roy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medtronic Diabetes, Northridge, California, USA. Hauptthemen laut MEDLINE: Algorithms, Blood Glucose, Diabetes Mellitus, Type 1, Hypoglycemic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Carbohydrate counting (CC) and meal announcements, before eating, introduce a significant burden for individuals managing type 1 diabetes (T1D). An automated insulin delivery system with automatic bolusing that eliminates the need for CC and premeal bolusing (i.e., a hands-free closed-loop [HFCL] system) was assessed in a feasibility trial of adults with T1D.
Methods
The system included the MiniMed™ 780G pump and a smartphone-paired smartwatch with the Klue application (Klue, Inc.) that detects eating and drinking gestures. A smartphone algorithm converted gestures into carb amounts that were transmitted to the pump for automatic bolusing. For 5 days, participants ( N = 17, 18–75 years of age) used the system at home with meal announcements based on traditional CC, with the Klue application disabled (Home-stay phase). Thereafter, participants moved to a supervised hotel setting, where the Klue application was enabled for 5 days and meals were not announced (Hotel-stay phase). Participants consumed the same eight test meals (six solid and two liquid) of varying caloric and carb size at the same time and day of the week for both phases, and glycemic metrics were compared. Otherwise, there were no other meal restrictions.
Results
The overall time in range (70–180 mg/dL) was 83.4% ± 7.0% and 80.6% ± 6.7% for the Home-stay and Hotel-stay, respectively ( P = 0.08). The average time at 180 mg/dL was 13.5% and 16.3% ( P = 0.1046), respectively. Postprandial glycemia following low-carb test meals was similar between the two phases. The system's ability to accommodate high-carb meals was somewhat limited. There were no episodes of severe hypoglycemia or diabetic ketoacidosis.
Conclusion
Preliminary findings show that a HFCL system was safe and maintained overall glycemic control, similar to that observed with traditional CC and manual meal bolusing. By eliminating these daily T1D burdens, a HFCL system may improve quality of life for individuals with T1D. ClinicalTrials.gov number: NCT04964128
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medtronic Diabetes, Northridge, California, USA.
- Division of Endocrinology, Diabetes, and Metabolism, Sheba Medical Center and Tel-Aviv University School of Medicine, Tel-Aviv, Israel.
- Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
ORCID-Profile: Anirban Roy, Robert Vigersky, Ohad Cohen
Zitieren
APA
Roy, A., Grosman, B., Benedetti, A., Engheta, B., Miller, D., Laron-Hirsh, M., Cohen, Y., Ré, R., Edd, S. N., Vigersky, R., Cohen, O., & Tirosh, A. (2024). An Automated Insulin Delivery System with Automatic Meal Bolus Based on a Hand-Gesturing Algorithm. Diabetes Technology & Therapeutics, 26(9), 633-643. https://doi.org/10.1089/dia.2023.0529
Vancouver
Roy A, Grosman B, Benedetti A, Engheta B, Miller D, Laron-Hirsh M, et al. An Automated Insulin Delivery System with Automatic Meal Bolus Based on a Hand-Gesturing Algorithm. Diabetes Technology & Therapeutics. 2024;26(9):633-643. doi:10.1089/dia.2023.0529
BibTeX
@article{Roy2024,
author = {Roy, Anirban and Grosman, Benyamin and Benedetti, Andrea and Engheta, Bahman and Miller, Diana and Laron-Hirsh, Maya and Cohen, Yael and Ré, Roseline and Edd, Shannon N and Vigersky, Robert and Cohen, Ohad and Tirosh, Amir},
title = {An Automated Insulin Delivery System with Automatic Meal Bolus Based on a Hand-Gesturing Algorithm},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
volume = {26},
number = {9},
pages = {633--643},
doi = {10.1089/dia.2023.0529}
}
EUVIMED